KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare ConferenceBusiness Wire • 09/10/24
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024Business Wire • 09/06/24
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational UpdateBusiness Wire • 09/05/24
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 09/04/24
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary AngioedemaBusiness Wire • 09/03/24
KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin SymposiumBusiness Wire • 08/29/24
KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary AngioedemaBusiness Wire • 08/15/24
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial ResultsBusiness Wire • 07/11/24
KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11Business Wire • 06/27/24
Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 LaunchSeeking Alpha • 06/24/24
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary AngioedemaBusiness Wire • 06/18/24
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024Business Wire • 06/06/24
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024Business Wire • 06/03/24
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary AngioedemaBusiness Wire • 05/31/24
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024Business Wire • 05/24/24
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/03/24
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference AmericasBusiness Wire • 03/18/24
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for SebetralstatBusiness Wire • 03/12/24
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational UpdateBusiness Wire • 03/11/24
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasBusiness Wire • 03/08/24
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive OfficerBusiness Wire • 03/07/24